Ann: AGM Presentation, page-41

First 41 Last

Share
Profile

Follow
Shellbell

7,747 Posts.

3296

14/12/22

15:31

Post #: 65311173
Share

Originally posted by hottod: ↑

Dzoanet, as you described it, PTX-200 might be considered as an "ingredient" of Cell-Pryme-M and CellPryme-A.

CellPryme-M is a manufacturing step in the preparation of cell therapies in which PTX-200, as an example of an AKT inhibitor and PH domain inhibitor, may be used in a medium in which cells are cultured.

CellPryme-A is an adjuvant therapy for cellular therapy in which PTX-200 may be used, but likely in combination with a checkpoint inhibitor.

These are new inventions and therefore require new names. I don’t have a problem with that.

If the supposition of PTX playing a crucial role in both CellPryme-M and CellPryme-A is correct, as a shareholder, I’m happy to see the company very cleverly working to derive maximum value from an existing asset.

Expand

Interesting to look back at the release re the two patents for PTX-200. Your supposition that our CellPryme Adjuvant is based on the targeted therapy tech of PTX-200 is correctomundo. So it could form part of the personalised therapy to be incorporated into our flagship CarT clinical trial for AML next year (not as a targeted therapy as our trial in AML is currently) but as an Adjuvant.

As you state, "I’m happy to see the company very cleverly working to derive maximum value from an existing asset"... I agree. It seems, however, that the second patent for PTX-200 is being utilised in the manner in which it was originally intended. Things are coming together, and whilst there are going to be different and stand-alone breakthroughs being made in the next-gen CarT therapy space, the potential reach that OmniCAR and CellPryme (with its personalised plug-and-play approach) across a very broad spectrum should not be underestimated.

Last edited by Shellbell: 14/12/22

PTX Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply